{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:55Z","timestamp":1789726435926,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cpcardiol.2022.101429","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T03:50:34Z","timestamp":1663991434000},"page":"101429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-7835","authenticated-orcid":false,"given":"Mahmoud","family":"Ismayl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhannad Aboud","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn","family":"Marar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandan S.","family":"Anavekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101429_bib0001","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101429_bib0002","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"New Eng J Med"},{"issue":"11","key":"10.1016\/j.cpcardiol.2022.101429_bib0003","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.5603\/KP.2014.0212","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy","volume":"72","author":"Elliott","year":"2014","journal-title":"Kardiologia Polska (Polish Heart Journal)"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101429_bib0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2009.05.006","article-title":"Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance","volume":"54","author":"Maron","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101429_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12551-014-0151-5","article-title":"The role of super-relaxed myosin in skeletal and cardiac muscle","volume":"7","author":"McNamara","year":"2015","journal-title":"Biop rev"},{"key":"10.1016\/j.cpcardiol.2022.101429_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.yjmcc.2016.03.009","article-title":"Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes","volume":"94","author":"McNamara","year":"2016","journal-title":"J mol cell cardiol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2022.101429_bib0007","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: Current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"10.1016\/j.cpcardiol.2022.101429_bib0008","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101429_bib0009","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA cardiol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2022.101429_bib0010","first-page":"896","article-title":"A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"JACC: Heart Failure"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101429_bib0011","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.amjmed.2017.12.031","article-title":"Clinical profile of nonresponders to surgical myectomy with obstructive hypertrophic cardiomyopathy","volume":"131","author":"Wells","year":"2018","journal-title":"Am j med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101429_bib0012","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"issue":"40","key":"10.1016\/j.cpcardiol.2022.101429_bib0013","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"issue":"35","key":"10.1016\/j.cpcardiol.2022.101429_bib0014","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proceed Nat Acad Sci"},{"issue":"11","key":"10.1016\/j.cpcardiol.2022.101429_bib0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Annals of Int Med"},{"issue":"21","key":"10.1016\/j.cpcardiol.2022.101429_bib0016","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10253","key":"10.1016\/j.cpcardiol.2022.101429_bib0017","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101429_bib0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101429_bib0019","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"Suppl_1","key":"10.1016\/j.cpcardiol.2022.101429_bib0020","doi-asserted-by":"crossref","first-page":"A10969","DOI":"10.1161\/circ.144.suppl_1.10969","article-title":"Estimated number needed to treat with Mavacamten vs placebo to improve functional capacity and left ventricular outflow tract obstruction in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"144","author":"Semigran","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101429_bib0021","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:58:53Z","timestamp":1758938333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622003267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0146280622003267"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101429","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101429"}}